Charles River Laboratories International, Inc. $CRL Stake Cut by Quantinno Capital Management LP

Posted by Stanley Muller on Jul 31st, 2026

Quantinno Capital Management LP lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 9.1% in the first quarter, HoldingsChannel.com reports. The firm owned 227,069 shares of the medical research company’s stock after selling 22,746 shares during the period. Quantinno Capital Management LP’s holdings in Charles River Laboratories International were worth $39,169,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Tema Etfs LLC bought a new position in shares of Charles River Laboratories International in the 4th quarter worth about $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $42,000. Sfam LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $43,000. Geneos Wealth Management Inc. raised its stake in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after acquiring an additional 145 shares during the period. Finally, Activest Wealth Management raised its stake in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 0.2%

Shares of NYSE:CRL opened at $235.17 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company’s 50-day moving average price is $205.16 and its 200 day moving average price is $187.83. The company has a market cap of $11.33 billion, a PE ratio of -62.55, a P/E/G ratio of 2.61 and a beta of 1.40. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $242.73.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the prior year, the firm earned $2.34 EPS. Charles River Laboratories International’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent research reports. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Barclays increased their price target on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Royal Bank Of Canada started coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $220.75.

Read Our Latest Stock Analysis on Charles River Laboratories International

Insider Activity

In other news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.